Product Description
HT-005 Z-Pods includes a novel topical delivery matrix (Z-Pods™) loaded with an endogenous ligand with suspected immune-modulating action. Z-Pods™ use patented xerogel-derived nanoparticles for sustained and controlled topical delivery of active pharmaceutical ingredients. (Sourced from: https://hoththerapeutics.com/pipeline/ht-005-z-pods/)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: N/A
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoth Therapeutics
Company Location: NEW YORK NY 10020
Company CEO: Robb Knie
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Lupus Erythematosus, Cutaneous
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/08/2021 |
News Article |
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics |
|
12/08/2021 |
News Article |
Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027 |
|
05/13/2021 |
News Article |
Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus |
|
02/02/2021 |
News Article |
Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline |